353 results about "Serum glucose" patented technology

The invention relates to the field of microorganisms, and discloses a strain of lactobacillus acidophilus and application of the lactobacillus acidophilus in preparation of drugs for preventing and / or treating hyperlipidemia and hyperglycemia, the preservation number of the lactobacillus acidophilus is CGMCC No.33155, the strain can generate lactic acid, is resistant to acid and cholate, and has strong self-aggregation ability and hydrophobic ability. The strain provided by the invention can promote the decomposition of fat and sugar by degrading cholesterol and inhibiting the activity of alpha-glucosidase and alpha-amylase, can reduce the expression levels of blood sugar, blood fat and inflammatory factors of hyperlipidemia and hyperglycemia mice, and provides a new idea for preparing medicines for preventing and / or treating hyperglycemia and hyperlipidemia.

Provided is the use of a conjugated cholic acid, tryptophan-conjugated bile acids (TrpCA) or a TrpCA-producing strain for preventing and / or treating a metabolic disease. The present disclosure relates to the use of tryptophan-conjugated cholic acid or its producing bacteria strain in the preparation of a composition for preventing and / or treating a metabolic disease, or for promoting GLP-1 and / or insulin production. The inventors have discovered for the first time that the tryptophan-conjugated cholic acid can significantly promote the secretion of GLP-1 in both in vivo animal model and in vitro cell model, thereby reducing weight, lowering blood glucose and relieving symptoms of non-alcoholic fatty liver disease. Moreover, colonization of the selected probiotics can also have the same metabolic improvement effects.

The invention provides a fructus cannabis protein peptide capable of reducing blood sugar and regulating glycometabolism and a preparation method and application thereof, and belongs to the technical field of functional active peptides, and the preparation method comprises the following steps: performing low-temperature supersonic fluid crushing on fructus cannabis, performing enzymolysis pretreatment on the crushed fructus cannabis, adding compound protease for enzymolysis, adding PNGaseF enzyme for further enzymolysis, and performing freeze drying to obtain the fructus cannabis protein peptide capable of reducing blood sugar and regulating glycometabolism. And carrying out membrane ultrafiltration interception and enrichment on the enzymolysis supernatant, carrying out tangential flow filtration, concentrating, drying and sterilizing to obtain the fructus cannabis protein peptide. Tests prove that the novel fructus cannabis protein peptide has the following remarkable effects that the fasting blood glucose level can be remarkably reduced, and uncomfortable symptoms such as thirst, polydipsia, diuresis and weakness caused by hyperglycemia are relieved; the symptoms of glucose intolerance and insulin resistance caused by hyperglycemia can be obviously relieved, and the onset risk of type 2 diabetes mellitus is reduced; the level of fasting serum insulin and glycosylated hemoglobin can be obviously reduced, and the level of serum GLP-1 can be improved.

The present invention relates to the use of lemon exosomes in the preparation of a drug for preventing, alleviating, or treating skin ulcers. The invention creatively extracts and purifies exosomes from lemons and studies their physiological effects. Lemon exosomes can reduce the expression of inflammatory factors in macrophages, promote the healing of skin ulcers, lower blood sugar, and promote skin angiogenesis. Lemon exosomes have the advantages of good efficacy, simple raw material acquisition, and minimal toxic and side effects.

The invention belongs to the field of biological medicine, and particularly provides application of a humanized DKK-1 monoclonal antibody in preparation of a medicine for treating Alzheimer's disease. A light chain sequence and a heavy chain sequence of the humanized DKK-1 monoclonal antibody are respectively shown as SEQ ID NO: 1-2, and animal experiments prove that the humanized DKK-1 monoclonal antibody can prolong the lifetime of a mouse with the Alzheimer's disease, improve the cognitive level of the mouse with the Alzheimer's disease, improve the memory ability of the mouse with the Alzheimer's disease and reduce blood sugar. The humanized DKK-1 monoclonal antibody has the effect of treating the Alzheimer's disease and can relieve the symptoms of the Alzheimer's disease.

A GLP-1, GIP and GCG receptor triagonist and a use thereof. The corresponding compound has an agonist effect on a human glucagon-like peptide-1 (GLP-1) receptor, a human glucose-dependent insulinotropic polypeptide (GIP) receptor and a human glucagon (GCG) receptor, and can be used for preventing and / or treating diseases or conditions related to metabolic disorders.

A computer implemented method matching an individual's continuous metabolite monitoring traces with another individual's continuous metabolite monitoring traces begins by identifying a concentration level of a metabolite for a subject. Dividing metabolic states into ranges of concentration levels allows for transforming a concentration level into a symbol from a set of symbols, wherein the symbol represents a category of concentration levels. The method identifies one or more strings of symbols, wherein each string of symbols represents a series of one or more symbols corresponding to a series of transformed concentration levels represented by the symbols. A computer is programmed to determine a lexical distance between a first string from the one or more strings of symbols and a second string, wherein the lexical distance corresponds to a degree of similarity between the first string and the second string. The computer provides a search result for a search query based on the determined lexical distance.

Apparatuses, systems, and methods for prosthetic valves having sensor systems are disclosed. Examples of prosthetic valves include replacement heart valves for replacing the function of a native heart valve, such as a mitral or tricuspid valve. In various embodiments, replacement heart valves are provided with sensors or markers for assisting with proper placement and / or securement in the body. A replacement heart valve may include anchors for securing the replacement heart valve to native leaflets, wherein sensors and / or markers provide feedback to the physician for confirming proper placement of the anchors during the implantation procedure. Sensors may also be used to assess the function of the prosthetic valve after deployment. Sensors may also be used to monitor blood pressure, temperature, oxygen, insulin, cholesterol, and / or glucose to assess overall patient health.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The present invention belongs to the field of biomedicine, and specifically relates to a new use of Keratin 7 protein, and a recombinant plasmid expressing Keratin 7 protein, a recombinant probiotic expressing Keratin 7 protein, and a use for preparing a medicine for treating and / or preventing metabolic diseases. The present invention first inserts the Keratin 7 gene into the expression vector pET‑28a to obtain a recombinant plasmid expressing Keratin 7; secondly, the recombinant plasmid is introduced into Escherichia coli Nissle 1917 (EcN) tolerant bacteria to obtain a functional recombinant probiotic. The recombinant probiotics described in the present invention can effectively reduce blood sugar while efficiently expressing Keratin 7 protein, and has a significant therapeutic effect on diabetes and its complications, and the effect is higher than that of clinical drugs, and has good clinical application prospects.

The invention discloses a phloretin derivative and application of the phloretin derivative in preparation of a medicine for treating diabetes and complications thereof, and relates to the technical field of small molecule medicines. The structure of the phloretin derivative is shown in the specification. Compared with existing phloretin (unmodified) and a clinically common alpha-glucosidase inhibitor (such as acarbose), the phloretin derivative obtained through structural modification can more efficiently inhibit the activity of alpha-glucosidase, further more effectively delays decomposition and absorption of starch substances, has a better stable regulation effect on postprandial blood sugar, and can be used for preparing the phloretin derivative. The core problem that the existing phloretin inhibitory activity is insufficient is solved.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and more particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of diabetes. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce blood glucose levels in type 2 diabetic rats and increase serum insulin levels and insulin sensitivity index in rats. Moreover, the compound combination drug for treating diabetes is an existing TCM preparation, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pills are easy to carry and convenient to take.

The invention provides an application of cichorium glandulosum polysaccharide in preparation, basic characterization and type 2 diabetes mellitus relieving medicines, and belongs to the technical field of medicines. Animal experiment results show that after the cichorium glandulosum polysaccharide is applied to type 2 diabetic mice, serum biochemical indexes can be adjusted, the blood sugar level can be reduced, organ injuries can be protected or repaired, and PI3K / AKT / mTOR signal channel related protein expression in the main glycometabolism target organ liver can be adjusted. Therefore, the prepared cichorium glandulosum polysaccharide can be used as a medicine for relieving type 2 diabetes mellitus.

The invention provides a preparation method of probiotic fermented polygonatum sibiricum polysaccharide, and belongs to the field of traditional Chinese medicinal material processing. The preparation method comprises the following steps: (1) adding cellulase and pectinase into polygonatum kingianum, carrying out water extraction, carrying out enzyme deactivation after water extraction, and carrying out suction filtration to obtain filtrate; (2) preparing bacillus DU-106 and lactobacillus plantarum nbk-MA2 into bacterial powder, and adding water to obtain bacterial liquid; mixing the bacterial liquid with the filtrate, fermenting, performing suction filtration, and centrifuging to obtain supernate; performing alcohol precipitation to remove protein; carrying out ethanol precipitation by using absolute ethyl alcohol again, collecting the precipitate after centrifuging, and carrying out redissolution, dialysis and freeze-drying to obtain fermentation modified crude polysaccharide; and (3) purifying the fermented and modified crude polysaccharide to obtain a purified polysaccharide component. The obtained probiotic fermented polygonatum sibiricum polysaccharide has the effect of losing weight, and can obviously improve the obesity characteristics of mice, specifically, reducing body weight, reducing fat, reducing serum liver lipid level, relieving serum liver inflammation of the mice, weakening blood glucose insulin sensitivity, repairing liver injury and the like.

The present invention provides an isolated Akkermansia muciniphila strain, composition comprising the same, and use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders induced by obesity, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases, brain aging, tumors, etc. Additionally, it can be used for preventing and treating metabolic disorders after discontinuation of GLP-1 receptor agonist drugs, preventing weight rebound and blood glucose rebound, and maintaining glucose homeostasis.

The invention relates to a probiotic preparation containing a BL11 strain and capable of improving obesity-related metabolism and senescence indexes of middle-aged and elderly people and application of the probiotic preparation. The strain in the probiotic preparation is composed of a bifidobacterium longum subsp. Longum BL11 strain and a pediococcus acidilactici PA53 strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of improving obesity-related metabolic indexes, which is specifically embodied in that: the weight increase and body fat rate of mice fed with high fat diet can be reduced; the low-density lipoprotein level, the total cholesterol level and the triglyceride level are reduced, and the high-density lipoprotein level is improved; fasting blood-glucose, glycosylated hemoglobin level and insulin resistance index are reduced; chronic inflammation is relieved; meanwhile, the composition also has excellent performance in the aspect of improving senescence-related indexes, the content of malondialdehyde in serum can be reduced, the activity of superoxide dismutase and glutathione peroxidase can be improved, and the activity of telomerase can be improved.

The embodiment of the invention relates to the field of microorganisms, in particular to lactobacillus pentosus A2 used for preventing or improving polycystic ovarian syndrome, a microbial agent, a dairy product and application of the lactobacillus pentosus A2, the microbial agent and the dairy product. The preservation number of the lactobacillus pentosus A2 is CGMCC (China General Microbiological Culture Collection Center) NO.27253. The lactobacillus pentosus A2 disclosed by the invention can correct irregular estrus cycles, improve ovarian polycystic lesions, sex hormone disorder and abnormal blood fat and blood sugar metabolism, can effectively reduce the LPS level in serum and oxidative stress injury of ovarian tissues, is a product capable of repairing ovarian functions and improving sex hormone secretion, and can be used for preventing, relieving or treating PCOS.

The invention discloses a GLP-1 GIP analogue, an FGF21 protein, a three-function protein and an application thereof. The trifunctional protein comprises a GLP-1 / GIP analogue and an FGF21 (Fibroblast Growth Factor 21) protein. The invention also discloses application of the GLP-1 / GIP analogue, the FGF21 protein and the three-function protein in preparation of medicines for preventing and / or treating diseases related to GLP-1, GIP and / or FGF21. The GLP-1 / GIP analogue, the FGF21 protein and the three-function protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, meet multiple requirements of patients with type 2 diabetes for reducing blood sugar, relieving liver fatty degeneration, reducing weight, improving circulating lipid metabolism disorder and the like, and are better in biological safety and tolerance and longer in in-vivo half-life period.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

The invention provides a lactic acid bacteria composition for adjuvant treatment of diabetes, a compound lactic acid bacteria probiotic agent and application, and belongs to the technical field of functional microorganisms. The lactic acid bacteria composition provided by the invention is obtained by compounding eight specific lactic acid bacteria strains, has the effects of reducing blood sugar, blood fat and insulin level for people with high blood sugar and diabetics, and also has the effect of regulating gastrointestinal tract disorder. Therefore, the compound lactic acid bacteria probiotic agent prepared on the basis of the lactic acid bacteria composition has a good blood sugar control effect on people with high blood sugar and patients with type II diabetes mellitus. Meanwhile, the compound lactic acid bacteria probiotic agent has no side effect, and the purpose of safe prevention and treatment can be achieved.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus mucus fermentation TY-M26 and application of the lactobacillus mucus fermentation TY-M26, and the preservation number of the lactobacillus mucus fermentation TY-M26 is CGMCC (China General Microbiological Culture Collection Center) No. 32238. The lactobacillus mucilaginosus TY-M26 has high inhibitory activity on alpha-glucosidase activity, and animal experiments prove that the lactobacillus mucilaginosus TY-M26 can significantly relieve diabetes characteristics of mice with type II diabetes, significantly reduce fasting blood-glucose level, significantly improve insulin resistance and serum insulin level, significantly reduce serum Glu level and serum TG level, and can be used for preparing medicines for treating diabetes mellitus. The pathological injury of pancreatic tissues is obviously improved; the lactobacillus mucilaginosus TY-M26 has the advantages that the lactobacillus mucilaginosus TY-M26 can be used for preparing the lactobacillus mucilaginosus TY-M26, the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues can be obviously improved, a certain protection effect on the liver is achieved, and the lactobacillus

The invention relates to a mitochondrial uncoupling inhibitor sustained-release nanodot, a preparation method thereof and application of the nanodot in type 2 diabetes mellitus, and belongs to the technical field of nano-drugs. According to the preparation method disclosed by the invention, glycine and genipin are subjected to Schiff reaction to prepare the slow-release nanodot, and the slow-release nanodot is of a monodisperse spherical structure, has surface negative charges, and can slowly release genipin under physiological conditions, so that the mitochondrial protection effect of the genipin is fully exerted. The mitochondrial uncoupling inhibitor slow-release nanodot prepared by the invention can obviously improve the mitochondrial membrane potential, increase the cell ATP content, effectively inhibit mtDNA release under the stimulation of IL-1beta and palmitic acid, effectively inhibit STING inflammation pathway activation under the stimulation of IL-1beta and PA, obviously reduce pancreatic beta cell apoptosis, obviously relieve endoplasmic reticulum stress, and can be used for preparing the mitochondrial uncoupling inhibitor slow-release nanodot. The T2DM mouse blood sugar is obviously reduced, the glucose tolerance dose and the insulin sensitivity are improved, and good biocompatibility is achieved.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

The invention discloses a serum glucose detection method based on MOFs nano-enzyme, and belongs to the technical field of serum glucose detection.The method comprises the following steps that GOD and human serum are mixed and react at 37 DEG C for 10 minutes, and GOD catalyzes glucose in the serum to react to generate H2O2; then, a mixed solution of MIL-53Fe and TMB is added into the system, and the reaction continues to be carried out for 10 minutes at the temperature of 37 DEG C; in the process, MIL-53Fe plays a catalytic role, H2O2 is promoted to be subjected to a reduction reaction to generate. OH, meanwhile, TMB is oxidized into oxTMB, the solution is turned into blue from colorless, and a remarkable absorption peak is formed at the wavelength of 652 nm. The concentration of glucose in serum is in positive correlation with the amount of generated. OH, so that under the catalytic action of MIL-53Fe, the amount of generated oxTMB is increased along with the increase of the concentration of glucose, and the blue color of the solution is deepened; the serum glucose detection method based on the MOFs nano-enzyme can be used for detection in a neutral solution, and has excellent accuracy, precision, sensitivity and reproducibility.

Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.

The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus acidophilus GOLDGUT-LA100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof. The Lactobacillus acidophilus GOLDGUT-LA100 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28398. The strain has strong acid resistance, can adapt to the digestive tract environment, and has high bile salt hydrolase activity. At the same time, in animal experiments, the strain significantly reduces blood glucose and serum cholesterol levels, reduces liver fat deposition, reduces adipose tissue inflammation, effectively reduces the weight, and has broad application prospects in the development of products for improving obesity, lowering lipid and lowering blood glucose.

The invention provides a coin-sized, fully integrated and wearable continuous blood glucose monitoring (CGM) system in combination with frontier technologies in crossing fields of biosensors, minimally invasive tools, hydrogels and the like. The invention comprises the following three main parts: 1) an emerging biochemical amplifier, namely an organic electrochemical transistor (OECT), for improving the sensitivity and exceeding the traditional electrochemical sensor; 2) a microneedle array for sampling interstitial fluid (ISF), which reduces pain in the skin penetration process; and 3) a tough and viscous enzyme hydrogel film which can improve the reliability of glucose sensing on the skin. Different from a traditional CGM, the CGM (OECT-CGM) provided by the invention has high anti-noise capability, adjustable sensitivity and current regeneration capability due to the adoption of the OECT amplifier, so that long-term stable glucose sensing can be realized within a specific clinical range (1-20mM). The CGM provided by the invention can provide high and adjustable sensitivity, minimally invasive property and better wearable property at the same time, and also paves a way for developing the next generation of CGM.

The invention relates to the field of microorganisms, in particular to a mucophilic protein Ackermann strain and application thereof, and the preservation number of the mucophilic protein Ackermann strain is CCTCC (China Center for Type Culture Collection) NO: M 20241304. The Ackermania muciniphila AKK-86 disclosed by the invention has good effects of promoting iron absorption, improving iron metabolism and relieving intestinal inflammation at the same time. In addition, the Ackermansiella muciniphila can also promote the generation of GLP-1, and has the potential of application in the aspects of reducing blood sugar and losing weight products.

This invention provides a coin-sized, fully integrated and wearable continuous glucose monitoring system (CGMs) via combining cutting-edge technologies from the intersecting fields of biosensors, minimally invasive tools, and hydrogels. The invention includes three major parts: 1) an emerging biochemical amplifier, the organic electrochemical transistor (OECT), to improve sensitivity beyond traditional electrochemical modules; 2) a microneedle array for interstitial-fluid (ISF) sampling with reduced pain during skin penetration; and 3) a tough, adhesive enzymatic-hydrogel-membrane to enhance reliability of glucose sensing on skin. Unlike conventional CGMs, the employed OECT amplifier empowers the CGM (OECT-CGMs) with a high anti-noise ability, an on-demand-tunable sensitivity and current regeneration ability, enabling long-term stable glucose sensing within specific clinical ranges (1˜20 mM). This work paves the way for the development of next-generation CGMs that can simultaneously deliver high and adjustable sensitivity, minimal invasiveness, and improved wearability.

The present application relates to a kind of pharmaceutical composition for treating type 2 diabetes and its application.The pharmaceutical composition includes icariin, hydroxymethyl coumarin and cinnamaldehyde, by three-component synergistic effect, simultaneously act on insulin resistance, pancreatic beta cell apoptosis and systemic metabolic inflammation three type 2 diabetes core pathological links, auxiliary reduce serum lipid level, and reduce drug-related liver injury risk, good safety.Animal experiment results show that three-drug combination group can effectively reduce blood sugar (decrease about 50%), significantly improve islet structure atrophy, restore hepatocyte index arrangement, reduce glomerular hypertrophy, significantly reduce serum TG and CHOL level (P<0.05) and inflammatory factor IL-6 and TNF-alpha level (P<0.05), and avoid the hepatotoxicity risk (ALT / AST restores to close to normal level) of hydroxymethyl coumarin.The present application is composed of three kinds of natural monomers with clear structure, and has clear components and controllable quality, which provides a more optimal comprehensive treatment strategy for the treatment of type 2 diabetes and its complications.